Surgical Science (Q3 Review): More to prove - Redeye
Bildkälla: Stockfoto

Surgical Science (Q3 Review): More to prove - Redeye

SUS reported Q3 sales and EBIT below our expectations. License revenue grew by 16%, and US sales within Educational Products remained strong. The quarter lacked the growth seen in Q2, and the miss opened the trapdoor for the share, falling c10%.

SUS reported Q3 sales and EBIT below our expectations. License revenue grew by 16%, and US sales within Educational Products remained strong. The quarter lacked the growth seen in Q2, and the miss opened the trapdoor for the share, falling c10%.
Börsvärldens nyhetsbrev